Financial statements Lek-Pharma
Balance sheet data of LEK-PHARMA
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2022
|
2023
|
|---|---|---|---|---|---|---|---|
| Total assets | 4 894 017,72 | 5 824 515,00 | 7 197 181,92 | 6 726 799,90 | 7 556 685,00 | 7 148 209,00 | 7 904 934,00 |
| A. Fixed assets | 204 267,01 | 88 357,00 | 55 749,00 | 31 609,00 | 29 027,00 | 20 326,00 | 11 696,00 |
| B. Current assets | 4 689 750,71 | 5 736 158,00 | 7 141 432,92 | 6 695 190,90 | 7 527 658,00 | 7 127 883,00 | 7 893 238,00 |
| C. Share capital contributions (basic funds) | 0,00 | - | - | - | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | - | - | - | 0,00 | 0,00 | 0,00 |
| Total liabilities | 4 894 017,72 | 5 824 515,00 | 7 197 181,92 | 6 726 799,90 | 7 556 685,00 | 7 148 209,00 | 7 904 934,00 |
| A. Equity | 138 949,47 | 987 528,00 | 1 363 710,00 | 2 111 925,45 | 2 026 334,00 | 2 088 506,00 | 2 623 267,00 |
| B. Liabilities and provisions for liabilities | 4 755 068,25 | 4 836 987,00 | 5 833 471,92 | 4 614 874,45 | 5 530 351,00 | 5 059 703,00 | 5 281 667,00 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 0,00 | - | - | - |
| II. Short-term liabilities | 4 755 068,25 | 4 836 987,00 | 4 569 962,92 | 4 148 041,17 | 5 530 351,00 | 5 059 703,00 | 5 281 667,00 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.